Cargando…

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer

Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs harbor a mutation in BRAF gene, a proto-oncogene involved in cell proliferation, differentiation and survival through the MAP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fanelli, Giuseppe Nicolò, Dal Pozzo, Carlo Alberto, Depetris, Ilaria, Schirripa, Marta, Brignola, Stefano, Biason, Paola, Balistreri, Mariangela, Dal Santo, Luca, Lonardi, Sara, Munari, Giada, Loupakis, Fotios, Fassan, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990491/ https://www.ncbi.nlm.nih.gov/pubmed/32015690 http://dx.doi.org/10.1186/s12935-020-1117-2

Ejemplares similares

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

Intratumor morphologic and transcriptomic heterogeneity in (V600E)BRAF-mutated metastatic colorectal adenocarcinomas
por: Angerilli, V., et al.
Publicado: (2021)

Tumor mutation burden: from comprehensive mutational screening to the clinic
por: Galuppini, Francesca, et al.
Publicado: (2019)

CK7 and consensus molecular subtypes as major prognosticators in (V600E)BRAF mutated metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2019)

Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives
por: Pellino, Antonio, et al.
Publicado: (2019)

Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases
por: Coati, Irene, et al.
Publicado: (2019)

A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study
por: Procaccio, Letizia, et al.
Publicado: (2021)

MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors
por: Angerilli, Valentina, et al.
Publicado: (2021)

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
por: Cremolini, Chiara, et al.
Publicado: (2019)

Noncoding RNAs as drivers of the phenotypic plasticity of oesophageal mucosa
por: Fassan, Matteo, et al.
Publicado: (2017)

Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases
por: Loupakis, Fotios, et al.
Publicado: (2021)

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
por: Cremolini, Chiara, et al.
Publicado: (2017)

The Morpho-Molecular Landscape of Spitz Neoplasms
por: Dal Pozzo, Carlo Alberto, et al.
Publicado: (2022)

BRAF-mutated metastatic colorectal cancer between past and future
por: Cremolini, Chiara, et al.
Publicado: (2015)

Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases
por: Fassan, Matteo, et al.
Publicado: (2018)

Correction to: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases
por: Fassan, Matteo, et al.
Publicado: (2019)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
por: De Simoni, Ottavia, et al.
Publicado: (2023)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2016)

Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience
por: Munari, Giada, et al.
Publicado: (2021)

LONG-NONCODING RNAs in gastroesophageal cancers
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2018)

Histopathological landscape of rare oesophageal neoplasms
por: Businello, Gianluca, et al.
Publicado: (2020)

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
por: Heinzerling, L, et al.
Publicado: (2013)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
por: Pellino, Antonio, et al.
Publicado: (2021)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis()()
por: Fassan, Matteo, et al.
Publicado: (2018)

BRAF Mutation Heterogeneity in Melanoma Lesions
por: SAKAIZAWA, Kaori, et al.
Publicado: (2020)

Design and Use of Nanostructured Single-Site Heterogeneous Catalysts for the Selective Transformation of Fine Chemicals
por: Santo, Vladimiro Dal, et al.
Publicado: (2010)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
por: Chiappetta, Caterina, et al.
Publicado: (2015)

Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial
por: Suenaga, Mitsukuni, et al.
Publicado: (2020)

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
por: Loupakis, Fotios, et al.
Publicado: (2013)

The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study
por: Lastraioli, Elena, et al.
Publicado: (2022)

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients
por: Schirripa, Marta, et al.
Publicado: (2018)

The landscape of BRAF transcript and protein variants in human cancer
por: Marranci, Andrea, et al.
Publicado: (2017)

CBX2-dependent transcriptional landscape: implications for human sex development and its defects
por: Sproll, Patrick, et al.
Publicado: (2019)

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin- and irinotecan-based treatment in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_443cc1tfvbrb8c8ujd3ubbin8a